Provided by Tiger Trade Technology Pte. Ltd.

Viking Therapeutics

27.37
-1.1750-4.12%
Volume:4.18M
Turnover:114.95M
Market Cap:3.45B
PE:-5.86
High:28.49
Open:28.48
Low:27.11
Close:28.54
52wk High:43.15
52wk Low:25.77
Shares:126.00M
Float Shares:123.00M
Volume Ratio:1.39
T/O Rate:3.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.6676
EPS(LYR):-3.1920
ROE:-88.85%
ROA:-51.86%
PB:8.44
PE(LYR):-8.57

Loading ...

Analyst Reiterates Buy on Viking Therapeutics, Citing Best-in-Class Obesity Pipeline and Multiple Value-Creation Catalysts

TIPRANKS
·
Jun 03

Viking Therapeutics Initiated at Buy by Lake Street

Dow Jones
·
May 29

Lake Street Initiates Viking Therapeutics With Buy Rating, $89 Price Target

MT Newswires Live
·
May 28

Viking Therapeutics (VKTX) Initiated with a Buy at Truist Financial

TIPRANKS
·
May 27

Viking Therapeutics shareholders elect Singleton, Rouan as Class II directors

Reuters
·
May 27

Is Viking Therapeutics (VKTX) Pricing In Too Much Optimism After Recent Share Price Swings?

Simply Wall St.
·
May 26

Should New Phase 2 Oral VK2735 Weight-Loss Data Require Action From Viking Therapeutics (VKTX) Investors?

Simply Wall St.
·
May 23

Viking Therapeutics to present at William Blair Growth Stock Conference

Reuters
·
May 21

How New Oral VK2735 Obesity Data At Viking Therapeutics (VKTX) Has Changed Its Investment Story

Simply Wall St.
·
May 15

Viking Therapeutics’ VK2735 demonstrates wieght loss in Phase 2 trial

TIPRANKS
·
May 12

Viking says oral VK2735 cuts weight up to 12.2% in Phase 2 trial

Reuters
·
May 12

BRIEF-Viking Therapeutics Presents Data From Its 13-Week Phase 2 Venture-Oral Dosing Trial

Reuters
·
May 12

Viking Therapeutics Presents Data From Its 13-Week Phase 2 Venture-Oral Dosing Trial of Vk2735 at European Congress on Obesity (Eco) 2026

THOMSON REUTERS
·
May 12

Viking Therapeutics presents Phase 2 oral VK2735 weight-loss data at ECO 2026

Reuters
·
May 05

Viking Therapeutics Announces Two Poster Presentations at European Congress on Obesity (Eco) 2026

THOMSON REUTERS
·
May 05

Viking Therapeutics call volume above normal and directionally bullish

TIPRANKS
·
May 05

Viking Therapeutics Price Target Maintained With a $125.00/Share by BTIG

Dow Jones
·
May 04

Maxim Group Sticks to Its Buy Rating for Viking Therapeutics (VKTX)

TIPRANKS
·
May 01

Ligand Pharma Ends TR‑Beta License With Viking Therapeutics

TIPRANKS
·
May 01

Ligand, Viking dispute TR-Beta program termination under license agreement

Reuters
·
May 01